Over the last decade, advances in cancer care have significantly improved overall survival. Importantly, this is driven by a shift of more patients into two key categories of treatment outcomes: cure or chronic management. In this paper, we explore four key trends that will help more patients reach cure or chronic management. In addition, we discuss the commercial implications of those trends for biopharma companies.
